PTGS2 and neoplasm: Combination strategies integrating COX-2 inhibitors with cytotoxic chemotherapeutics (e.g., alkylating agents, antimetabolites, anti-tumor antibiotics), monoclonal antibodies, and other antineoplastic agents are being actively investigated to optimize therapeutic efficacy while minimizing treatment-related toxicities [358].